Morgantown, WV, United States of America

Kathleen Ocasio

This inventor holds 1 USPTO granted patent. Top assignee: Viatris Inc.. Active years: 2026.


Average Co-Inventor Count = 1.0


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Kathleen Ocasio: Innovator in Pain Management

Introduction

Kathleen Ocasio is a notable inventor based in Morgantown, WV (US). She has made significant contributions to the field of pain management through her innovative research and development. Her work focuses on improving treatment methods for various types of pain, showcasing her dedication to enhancing patient care.

Latest Patents

Kathleen Ocasio holds 1 patent for her invention titled "Methods of using meloxicam for pain treatment and management." This patent relates to a method for managing pain, such as acute pain, post-operative pain, or post-procedure pain, by administering meloxicam. Her invention aims to provide effective solutions for individuals suffering from pain, demonstrating her commitment to medical advancements.

Career Highlights

Ocasio is currently employed at Viatris Inc., where she continues to work on innovative solutions in the pharmaceutical industry. Her role at the company allows her to collaborate with other professionals and contribute to the development of effective pain management therapies.

Collaborations

Throughout her career, Kathleen has worked alongside talented colleagues, including Susanne Vogt and Jeffrey P. Smith. These collaborations have fostered a creative environment that encourages the exchange of ideas and the pursuit of groundbreaking innovations.

Conclusion

Kathleen Ocasio's contributions to pain management through her patent and work at Viatris Inc. highlight her role as a dedicated inventor. Her innovative methods for using meloxicam represent a significant advancement in the field, ultimately benefiting patients in need of effective pain relief.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…